Jafari Ali, Abbastabar Maryam, Alaghi Alireza, Heshmati Javad, Crowe Francesca L, Sepidarkish Mahdi
Student Research Committee, Department of Community Nutrition, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Phytother Res. 2024 Dec;38(12):6048-6061. doi: 10.1002/ptr.8340. Epub 2024 Oct 31.
The aim of this meta-analysis was to determine the effect of curcumin on a range of health outcomes. PubMed, EMBASE, Scopus, and Web of Science were searched from inception until September 2023. Randomized clinical trials (RCTs) that compared the effect of Curcuma longa L. with placebo were considered eligible. The risk of bias and overall certainty of evidence were assessed using the Newcastle-Ottawa Scale and Grading of Recommendations Assessment, Development, and Evaluation (GRADE), respectively. We meta-analyzed the effect sizes across eligible studies using the random-effects model. In total, 103 RCTs on 42 outcomes were included, incorporating a total population of 7216 participants. Overall, 23 out of 42 (55%) outcomes reported statistically significant effect sizes. The credibility of the evidence was rated as high for fasting blood sugar (FBS), C-reactive protein (CRP), high-density lipoprotein (HDL), and weight. The remaining outcomes presented moderate (waist circumference [WC], hip circumference [HC], body mass index [BMI], insulin, Homeostatic Model Assessment for Insulin Resistance [HOMA-IR], quantitative insulin-sensitivity check index [QUICKI], leptin, gamma-glutamyl transferase [GGT], glutathione [GSH], and superoxide dismutase [SOD]), low (14 outcomes), or very low (14 outcomes) evidence. In conclusion, curcumin supplementation can modify FBS and some glycemic indices, lipid parameters, as well as inflammatory and oxidative parameters. This updated summary of the accumulated evidence may help inform clinicians and future guidelines regarding medical and scientific interest in curcumin. However, due to limitations in the methodological quality of the included studies, well-designed and long-term RCTs with large sample sizes are needed. Trial registration: PROSPERO: CRD42021251969.
本荟萃分析的目的是确定姜黄素对一系列健康结局的影响。检索了PubMed、EMBASE、Scopus和Web of Science数据库，检索时间从建库至2023年9月。比较姜黄与安慰剂效果的随机临床试验（RCT）被视为符合纳入标准。分别使用纽卡斯尔-渥太华量表和推荐分级评估、制定与评价（GRADE）系统评估偏倚风险和证据的总体确定性。我们使用随机效应模型对符合条件的研究中的效应量进行荟萃分析。总共纳入了103项关于42个结局的RCT，涉及7216名参与者。总体而言，42个结局中有23个（55%）报告了具有统计学意义的效应量。空腹血糖（FBS）、C反应蛋白（CRP）、高密度脂蛋白（HDL）和体重方面的证据可信度被评为高。其余结局的证据为中等（腰围[WC]、臀围[HC]、体重指数[BMI]、胰岛素、胰岛素抵抗稳态模型评估[HOMA-IR]、定量胰岛素敏感性检查指数[QUICKI]、瘦素、γ-谷氨酰转移酶[GGT]、谷胱甘肽[GSH]和超氧化物歧化酶[SOD]）、低（14个结局）或极低（14个结局）。总之，补充姜黄素可改善FBS和一些血糖指标、脂质参数以及炎症和氧化参数。这一最新的累积证据总结可能有助于为临床医生和未来关于姜黄素医学和科学研究兴趣的指南提供参考。然而，由于纳入研究的方法学质量存在局限性，需要设计良好的大样本长期RCT。试验注册号：PROSPERO：CRD42021251969。
